Iris Energy Limited vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Iris Energy Limited trades at $34.9 (market cap $14.07B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.59 (market cap $2.27B). The key difference: Iris Energy Limited is far larger — about 6.2× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Iris Energy Limited nearer its low. Which is the better fit depends on your goals.
| IREN | SLS | |
|---|---|---|
Market Cap | $14.07B | $2.27B |
Volume | 54,492,460 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $76.41 | $15.46 |
52-Week Low | $29.31 | $1.39 |
Typical Hold Time | 28 Days | — |
Enterprise Value | $16.02B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
IREN stock trades at $35.05, down 9.41% in 24 hours amid a bearish technical signal. The company is executing a pivot from Bitcoin mining to AI cloud services, with a $9.7 billion Microsoft deal, but faces ballooning losses and negative net margins. Analyst consensus remains bullish with an $81 price target, yet recent earnings misses and high valuations (P/E 51.42) highlight execution risks.
Outlook: Long-term growth potential from AI infrastructure demand is significant, but near-term profitability challenges and capital intensity pose risks. Investors should weigh strong analyst support against weak earnings trends and high cash burn from aggressive expansion plans.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →